CardioCell reports positive Phase IIa trial results of itMSCs to treat chronic heart failure

US-based biotechnology company CardioCell has reported positive results from its Phase IIa clinical trial of ischemia-tolerant mesenchymal stem cells (itMSCs) for chronic heart failure (HF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news